(Hong Kong, 29 July 2024) – AusMed Global, a partner company of the Hong Kong Science and Technology Parks Corporation (HKSTP) signed a strategic partnership with Merck, the leading science and technology company. This partnership enhances broader access of the world’s leading non-invasive diabetes management solutions to international markets and accelerating advancements in diabetes and obesity cares.
AusMed's KetoMetrics, the pioneering non-invasive breath ketone management system utilizes photonic sensing technology to measure breath acetone, offering a painless alternative to traditional blood testing. Similar to blood prick tests, the 'one test, one kit' approach minimizes carryover contamination. Additionally, the use of single-use breath samplers enhances the hygiene of each test, making KetoMetrics a proper choice for measurement in the point-of-care setting. This cutting-edge solution will bring advancements in diabetes and lifestyle management.
Ms. Christine Yip, CEO & Founder of AusMed, said, “KetoMetrics is the company's revolutionary solution for diabetes and lifestyle management, offering a non-invasive and efficient method to enhance patient care and improve health outcomes. This partnership with Merck, supported by HKSTP, marks a significant milestone in our journey, enhancing broader access to the non-invasive diabetes management solutions and accelerating advancements in diabetes and obesity cares. We are excited about the potential of this collaboration to set new standards in healthcare innovation and patient care, and to continue pushing the boundaries of what's possible in diabetes and obesity management.
Mr. Tony Cheng, Managing Director of Merck HK, said “As a science and technology company, Merck believes to advance the patients’ health through partnership, we are keen to promote the best start-up company that augment the landscape of diabetic care. We look forward to providing beyond the pills solution that will benefit patients in need and make a positive impact on the wider community.” Tony also highlighted the strategic partnership between Merck and AusMed is strengthened by their longstanding relationship with HKSTP. It aims to accelerate the commercialization of innovative solutions for diabetes management, potentially transforming the care landscape for patients.
Dr Grace Lau, Head of Institute for Translational Research of HKSTP said, “We are thrilled to see the partnership between Merck and AusMed. This collaboration will bring AusMed's innovative healthcare solution to an even wider customer base and make a more impactful contribution to the community. HKSTP is committed to fostering healthcare innovation. This introduction set the stage for a day of groundbreaking revelations and collaborative discussions.”
HKSTP is committed to propelling the park companies to expand their sales networks and enhance their visibility and connectivity with industry leaders. With AusMed's professional knowledge, rich industry experience in the pharmaceutical field, and world-class technology, this strategic partnership is an excellent example of the vibrant innovation and technology (I&T) ecosystem attract high-potential startups, accelerate their growth, and bring widespread benefits to patients. This collaboration further cements Hong Kong's position as an international hub of biomedical innovation.
